Published in Nat Rev Clin Oncol on July 05, 2016
Dual inhibiting OCT4 and AKT potently suppresses the propagation of human cancer cells. Sci Rep (2017) 0.76
Caffeic Acid Expands Anti-Tumor Effect of Metformin in Human Metastatic Cervical Carcinoma HTB-34 Cells: Implications of AMPK Activation and Impairment of Fatty Acids De Novo Biosynthesis. Int J Mol Sci (2017) 0.75
Looking beyond the cancer cell for effective drug combinations. Genome Med (2016) 0.75
Current status of research and treatment for non-small cell lung cancer in never-smoking females. Cancer Biol Ther (2017) 0.75
Phase Ib study of the mitochondrial inhibitor ME-344 plus topotecan in patients with previously treated, locally advanced or metastatic small cell lung, ovarian and cervical cancers. Invest New Drugs (2017) 0.75
Hallmarks of cancer: the next generation. Cell (2011) 140.01
Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med (2005) 25.93
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med (2002) 19.60
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med (2015) 14.71
Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med (2011) 13.74
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med (2012) 13.48
The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer (2012) 10.90
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature (2012) 9.39
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol (2011) 7.10
Cancer drug resistance: an evolving paradigm. Nat Rev Cancer (2013) 6.77
The causes and consequences of genetic heterogeneity in cancer evolution. Nature (2013) 5.91
Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med (2014) 5.65
Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med (2014) 5.43
Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer (2012) 5.15
Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med (2015) 4.97
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med (2014) 4.71
Synthetic lethal screen identification of chemosensitizer loci in cancer cells. Nature (2007) 4.70
Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov (2013) 4.39
Evaluating cell lines as tumour models by comparison of genomic profiles. Nat Commun (2013) 4.35
Patient-derived models of acquired resistance can identify effective drug combinations for cancer. Science (2014) 4.34
Patient-derived tumour xenografts as models for oncology drug development. Nat Rev Clin Oncol (2012) 4.00
Multicomponent therapeutics for networked systems. Nat Rev Drug Discov (2005) 3.99
Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol (2014) 3.79
The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov (2013) 3.71
Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med (2013) 3.51
Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood (2003) 3.37
The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer. Clin Cancer Res (2012) 3.36
Evolution of the cancer genome. Nat Rev Genet (2012) 3.24
Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet (2015) 3.13
Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat Med (2011) 3.12
Tumor adaptation and resistance to RAF inhibitors. Nat Med (2013) 3.11
The GATA2 transcriptional network is requisite for RAS oncogene-driven non-small cell lung cancer. Cell (2012) 3.10
Combinatorial drug therapy for cancer in the post-genomic era. Nat Biotechnol (2012) 3.10
Patient-derived xenograft models: an emerging platform for translational cancer research. Cancer Discov (2014) 2.98
High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response. Nat Med (2015) 2.95
Mutant BRAF melanomas--dependence and resistance. Cancer Cell (2011) 2.87
Bortezomib: proteasome inhibition as an effective anticancer therapy. Annu Rev Med (2006) 2.72
Evolutionary dynamics of carcinogenesis and why targeted therapy does not work. Nat Rev Cancer (2012) 2.71
Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors. J Clin Oncol (2013) 2.44
Models from experiments: combinatorial drug perturbations of cancer cells. Mol Syst Biol (2008) 2.33
Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma. Nat Med (2012) 2.26
The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis. Acta Oncol (2014) 2.14
Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study. Lancet Oncol (2014) 2.10
Genetics and biomarkers in personalisation of lung cancer treatment. Lancet (2013) 2.09
Genotype-selective combination therapies for melanoma identified by high-throughput drug screening. Cancer Discov (2012) 1.97
Discovery of cancer drug targets by CRISPR-Cas9 screening of protein domains. Nat Biotechnol (2015) 1.83
The clinical development of MEK inhibitors. Nat Rev Clin Oncol (2014) 1.79
Systems pharmacology of adverse event mitigation by drug combinations. Sci Transl Med (2013) 1.78
Classifying Cancers Based on T-cell Infiltration and PD-L1. Cancer Res (2015) 1.77
Identification of optimal drug combinations targeting cellular networks: integrating phospho-proteomics and computational network analysis. Cancer Res (2010) 1.59
PI3'-kinase inhibition forestalls the onset of MEK1/2 inhibitor resistance in BRAF-mutated melanoma. Cancer Discov (2014) 1.58
Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo. J Immunol (2014) 1.58
Resistance to Targeted Therapies: Refining Anticancer Therapy in the Era of Molecular Oncology. Clin Cancer Res (2009) 1.56
RNAi screening comes of age: improved techniques and complementary approaches. Nat Rev Mol Cell Biol (2014) 1.54
Myc and mTOR converge on a common node in protein synthesis control that confers synthetic lethality in Myc-driven cancers. Proc Natl Acad Sci U S A (2013) 1.53
Inhibition of Lapatinib-Induced Kinome Reprogramming in ERBB2-Positive Breast Cancer by Targeting BET Family Bromodomains. Cell Rep (2015) 1.52
Perturbation biology nominates upstream-downstream drug combinations in RAF inhibitor resistant melanoma cells. Elife (2015) 1.46
PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types. Cancer Chemother Pharmacol (2013) 1.46
Applying synthetic lethality for the selective targeting of cancer. N Engl J Med (2014) 1.44
Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations-a review. Transl Lung Cancer Res (2015) 1.43
Determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategies. Cell Res (2012) 1.41
Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. Cancer Discov (2015) 1.30
Adaptive Immune Resistance: How Cancer Protects from Immune Attack. Cancer Discov (2015) 1.28
Maintaining Tumor Heterogeneity in Patient-Derived Tumor Xenografts. Cancer Res (2015) 1.26
Identification of multiple mechanisms of resistance to vemurafenib in a patient with BRAFV600E-mutated cutaneous melanoma successfully rechallenged after progression. Clin Cancer Res (2013) 1.25
Immune evasion in cancer: Mechanistic basis and therapeutic strategies. Semin Cancer Biol (2015) 1.22
Synthetic lethality in ATM-deficient RAD50-mutant tumors underlies outlier response to cancer therapy. Cancer Discov (2014) 1.21
A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors. Clin Cancer Res (2014) 1.19
Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR-Mutant Lung Cancer. Cancer Discov (2015) 1.18
Inhibition of HSP90 by AT13387 delays the emergence of resistance to BRAF inhibitors and overcomes resistance to dual BRAF and MEK inhibition in melanoma models. Mol Cancer Ther (2014) 1.18
Pathway and network analysis of cancer genomes. Nat Methods (2015) 1.17
Protein folding sculpting evolutionary change. Cold Spring Harb Symp Quant Biol (2010) 1.17
Drugging PI3K in cancer: refining targets and therapeutic strategies. Curr Opin Pharmacol (2015) 1.16
Severe cutaneous and neurologic toxicity in melanoma patients during vemurafenib administration following anti-PD-1 therapy. Cancer Immunol Res (2013) 1.12
Translational implications of tumor heterogeneity. Clin Cancer Res (2015) 1.12
It's about time: lessons for solid tumors from chronic myelogenous leukemia therapy. Mol Cancer Ther (2012) 1.10
HSP90 empowers evolution of resistance to hormonal therapy in human breast cancer models. Proc Natl Acad Sci U S A (2014) 1.09
Immune checkpoint modulation: rational design of combination strategies. Pharmacol Ther (2015) 1.08
The novel combination of chlorpromazine and pentamidine exerts synergistic antiproliferative effects through dual mitotic action. Cancer Res (2007) 1.06
Antitumor activity in RAS-driven tumors by blocking AKT and MEK. Clin Cancer Res (2014) 1.05
Targeting PI3K/mTOR overcomes resistance to HER2-targeted therapy independent of feedback activation of AKT. Clin Cancer Res (2014) 1.05
Safety and feasibility of targeted agent combinations in solid tumours. Nat Rev Clin Oncol (2013) 1.01
A phase I/II trial of pazopanib in combination with lapatinib in adult patients with relapsed malignant glioma. Clin Cancer Res (2013) 1.00
Parallel RNA interference screens identify EGFR activation as an escape mechanism in FGFR3-mutant cancer. Cancer Discov (2013) 0.98
Combining immunotherapy and anticancer agents: the right path to achieve cancer cure? Ann Oncol (2015) 0.97
Enhancing Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer: Cotargeting Signaling Pathways. J Natl Cancer Inst (2015) 0.95
Harnessing genetically engineered mouse models for preclinical testing. Chem Biol Interact (2007) 0.91
Targeting IGF-1R: throwing out the baby with the bathwater? Br J Cancer (2011) 0.91
Vemurafenib: a new treatment for BRAF-V600 mutated advanced melanoma. Cancer Manag Res (2012) 0.91
Phase I and pharmacokinetic study of pazopanib and lapatinib combination therapy in patients with advanced solid tumors. Invest New Drugs (2012) 0.91
Systems biology approaches for advancing the discovery of effective drug combinations. J Cheminform (2015) 0.90
The influence of subclonal resistance mutations on targeted cancer therapy. Nat Rev Clin Oncol (2015) 0.89
From theoretical synergy to clinical supra-additive toxicity. J Clin Oncol (2009) 0.88
Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma. Cancer Chemother Pharmacol (2014) 0.87
Combining RNA interference and kinase inhibitors against cell signalling components involved in cancer. BMC Cancer (2005) 0.83
Titration of signalling output: insights into clinical combinations of MEK and AKT inhibitors. Ann Oncol (2015) 0.83
Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer. J Clin Oncol (2015) 0.83
Phase I study evaluating the combination of lapatinib (a Her2/Neu and EGFR inhibitor) and everolimus (an mTOR inhibitor) in patients with advanced cancers: South West Oncology Group (SWOG) Study S0528. Cancer Chemother Pharmacol (2013) 0.81